218 related articles for article (PubMed ID: 25555909)
1. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of human cytochrome P450 2D6 with prinomastat bound.
Wang A; Savas U; Hsu MH; Stout CD; Johnson EF
J Biol Chem; 2012 Mar; 287(14):10834-43. PubMed ID: 22308038
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling of human CYP2D6 and molecular docking of a series of ajmalicine- and quinidine-like inhibitors.
Saraceno M; Coi A; Bianucci AM
Int J Biol Macromol; 2008 May; 42(4):362-71. PubMed ID: 18346782
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.
Hutzler JM; Walker GS; Wienkers LC
Chem Res Toxicol; 2003 Apr; 16(4):450-9. PubMed ID: 12703961
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
6. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
7. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
[TBL] [Abstract][Full Text] [Related]
9. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
10. Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site.
Berka K; Anzenbacherová E; Hendrychová T; Lange R; Mašek V; Anzenbacher P; Otyepka M
J Inorg Biochem; 2012 May; 110():46-50. PubMed ID: 22459173
[TBL] [Abstract][Full Text] [Related]
11. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
12. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
Strobl GR; von Kruedener S; Stöckigt J; Guengerich FP; Wolff T
J Med Chem; 1993 Apr; 36(9):1136-45. PubMed ID: 8487254
[TBL] [Abstract][Full Text] [Related]
13. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
14. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine.
Liu Y; Cui T; Peng Y; Ji M; Zheng J
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22251. PubMed ID: 30368994
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution.
Fischer A; Smieško M
Sci Rep; 2019 Nov; 9(1):16411. PubMed ID: 31712722
[TBL] [Abstract][Full Text] [Related]
17. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
[TBL] [Abstract][Full Text] [Related]
18. Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.
Don CG; Smieško M
PLoS One; 2018; 13(8):e0202534. PubMed ID: 30133539
[TBL] [Abstract][Full Text] [Related]
19. Modelling species selectivity in rat and human cytochrome P450 2D enzymes.
Edmund GH; Lewis DF; Howlin BJ
PLoS One; 2013; 8(5):e63335. PubMed ID: 23691026
[TBL] [Abstract][Full Text] [Related]
20. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
